These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 28711518)
1. Antagonism of the 5-HT de Jong IEM; Mørk A Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518 [TBL] [Abstract][Full Text] [Related]
2. The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Herrik KF; Mørk A; Richard N; Bundgaard C; Bastlund JF; de Jong IEM Neuropharmacology; 2016 Aug; 107():351-363. PubMed ID: 27039041 [TBL] [Abstract][Full Text] [Related]
3. The 5-HT Amat-Foraster M; Leiser SC; Herrik KF; Richard N; Agerskov C; Bundgaard C; Bastlund JF; de Jong IEM Neuropharmacology; 2017 Feb; 113(Pt A):45-59. PubMed ID: 27647493 [TBL] [Abstract][Full Text] [Related]
5. Idalopirdine as a treatment for Alzheimer's disease. Galimberti D; Scarpini E Expert Opin Investig Drugs; 2015; 24(7):981-7. PubMed ID: 26022777 [TBL] [Abstract][Full Text] [Related]
6. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Khoury R; Grysman N; Gold J; Patel K; Grossberg GT Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076 [TBL] [Abstract][Full Text] [Related]
7. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060 [TBL] [Abstract][Full Text] [Related]
8. Effects of the 5-HT Mørk A; Russell RV; de Jong IE; Smagin G Eur J Pharmacol; 2017 Mar; 799():1-6. PubMed ID: 28188762 [TBL] [Abstract][Full Text] [Related]
9. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease. Wicke K; Haupt A; Bespalov A Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Wilkinson D; Windfeld K; Colding-Jørgensen E Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016 [TBL] [Abstract][Full Text] [Related]
11. The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity-A Functional MRI Study in the Awake Rat. Ferris CF; Kulkarni P; Yee JR; Nedelman M; de Jong IEM Front Pharmacol; 2017; 8():279. PubMed ID: 28659792 [TBL] [Abstract][Full Text] [Related]
12. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease. Calhoun A; Ko J; Grossberg GT Expert Opin Emerg Drugs; 2017 Mar; 22(1):101-105. PubMed ID: 28253832 [TBL] [Abstract][Full Text] [Related]
13. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. Hirano K; Piers TM; Searle KL; Miller ND; Rutter AR; Chapman PF Life Sci; 2009 Apr; 84(15-16):558-62. PubMed ID: 19302808 [TBL] [Abstract][Full Text] [Related]
14. Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT Więckowska A; Kołaczkowski M; Bucki A; Godyń J; Marcinkowska M; Więckowski K; Zaręba P; Siwek A; Kazek G; Głuch-Lutwin M; Mierzejewski P; Bienkowski P; Sienkiewicz-Jarosz H; Knez D; Wichur T; Gobec S; Malawska B Eur J Med Chem; 2016 Nov; 124():63-81. PubMed ID: 27560283 [TBL] [Abstract][Full Text] [Related]
15. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders. Nirogi R; Jayarajan P; Shinde A; Mohammed AR; Grandhi VR; Benade V; Goyal VK; Abraham R; Jasti V; Cummings J Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830678 [TBL] [Abstract][Full Text] [Related]
16. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589 [TBL] [Abstract][Full Text] [Related]